BioXcel CFO exercises 9,000 RSUs into shares

BioXcel Therapeutics, Inc. Chief Financial Officer Richard I. Steinhart exercised 9,000 Restricted Stock Units into Common Stock.

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. Chief Financial Officer Richard I. Steinhart exercised 9,000 Restricted Stock Units into Common Stock. The RSUs, each representing one share of common stock, were granted on August 1, 2025 and vested in full approximately nine months after the grant date, contingent on continued employment. Following this compensation-related conversion, Steinhart directly holds 15,645 shares of BioXcel Therapeutics common stock.

Insider Trade Summary

9,000 shares exercised/converted

Exercise 2 txns

Insider Steinhart Richard I

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	9,000	$0.00	$0.00
Exercise	Common Stock	9,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 15,645 shares (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. F2. On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.

Key Figures

RSUs exercised: 9,000 units Shares held after transaction: 15,645 shares Grant size: 9,000 RSUs

3 metrics

RSUs exercised 9,000 units Restricted Stock Units converted into Common Stock

Shares held after transaction 15,645 shares Common Stock directly owned by CFO after exercise

Grant size 9,000 RSUs Granted on August 1, 2025, vesting in full after nine months

Key Terms

Restricted Stock Unit, RSU, derivative exercise/conversion, Common Stock

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

Common Stock financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioXcel Therapeutics (BTAI) CFO Richard Steinhart report on this Form 4?

BioXcel Therapeutics CFO Richard I. Steinhart reported exercising 9,000 Restricted Stock Units into Common Stock. This derivative exercise reflects previously granted equity compensation converting into actual shares rather than an open-market stock purchase or sale.

How many BioXcel Therapeutics (BTAI) shares does the CFO hold after this RSU exercise?

After the reported RSU exercise, CFO Richard I. Steinhart directly holds 15,645 shares of BioXcel Therapeutics Common Stock. This total reflects his updated equity position following conversion of 9,000 Restricted Stock Units into shares.

What are the terms of the 9,000 RSUs granted to the BioXcel Therapeutics (BTAI) CFO?

The 9,000 RSUs granted to the CFO on August 1, 2025 vest 100% on or within thirty days of nine months from the grant date. Vesting required his continued employment with BioXcel Therapeutics or a subsidiary through that vesting date.

Does the Form 4 show any open-market buying or selling of BioXcel Therapeutics (BTAI) shares?

The Form 4 does not show open-market buying or selling. It reports a derivative exercise coded “M,” where 9,000 Restricted Stock Units converted into Common Stock as part of the CFO’s equity compensation, rather than a market trade.

What does each Restricted Stock Unit represent for BioXcel Therapeutics (BTAI) CFO’s grant?

Each Restricted Stock Unit in this grant represents a contingent right to receive one share of BioXcel Therapeutics Common Stock. Upon vesting and settlement, the RSUs convert into an equal number of common shares held directly by the CFO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 07:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Steinhart Richard I

(Last) (First) (Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN CONNECTICUT 06511

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		M		9,000	A	(1)	15,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/01/2026		M			9,000	(2)	(2)	Common Stock	9,000	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.

	/s/ Richard Steinhart	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)